An ultra-sensitive fluid-filtration detection method used to determine the activity of hCE1 and to e

A new international medical study has found that the associated results are of important reference value for disease prevention. Human hepatolipase1 (hCE1) is highly expressed in the liver and can be released into the bloodstream through damage to liver cells, suggesting that hCE1 has a potential biomarker role in liver damage. However, there are currently some deficiencies in the methods of measurement of hCE1 activity, such as its selectivity and low sensitivity to interference with serum protein proteins (HSA), while the sensitivity of serum choline kinase (BChE) and phosphate kinase (PON1) is low.

These insufficiencies place some limitations on the current methods of measurement of hCE1 activity in terms of selectivity and sensitivity, interference factors and monitoring indicators, thus limiting the accurate measurement and evaluation of the role of hCE1 in potential biomarkers in liver damage. Therefore, future studies need to further investigate the current inadequacies in methods of measurement of hCE1 activity and how to overcome these in order to improve the accurate measurement and evaluation of the role of potential biomarkers of hCE1 in liver damage, thus providing a more accurate, scientific and comprehensive reference and theoretical basis for early diagnosis and treatment of liver damage. This study designed and synthesized a new type of fluorescent marker probe, NCMNe, and successfully constructed a method for quantifying serum HCE1 activity and evaluating its viability as a liver damage biomarkers study (LC-FD).

Through specificity studies, we found that NCMNe was highly selective in the hydrolysis of HCE1 and highly selective in the hydrolysis of HCE1 without HSA interference. HSA, PON1 and BChE were also highly selective in the hydrolysis of HCE1, confirming the viability of NCMNe as a liver damage biomarkers. 0.

0001M represents the most sensitive methods currently reported for measuring HCV activity, such as measuring HCV activity by fluid-phospho-synaptic spectroscopy. The results of clinical sample analysis show significant differences in HCV activity in HBV-infected patients. It should be noted that the above information is based on international public research findings, for reference in the Health Code, and does not constitute a clinical recommendation.